Literature DB >> 26951715

Variation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomy.

T M Morgan1, S R Hawken1, K R Ghani1, D C Miller1, F Y Feng2, S M Linsell1, J A Salisz3, Y Gao1, J E Montie1, M L Cher4.   

Abstract

BACKGROUND: We used data from the Michigan Urological Surgery Improvement Collaborative (MUSIC) to investigate the use of adjuvant and salvage radiotherapy (ART, SRT) among patients with high-risk pathology following radical prostatectomy (RP).
METHODS: For patients with pT3a disease or higher and/or positive surgical margins, we examined post-RP radiotherapy administration across MUSIC practices. We excluded patients with <6 months follow-up, and those that failed to achieve a postoperative PSA nadir ⩽0.1. ART was defined as radiation administered within 1 year post RP, with all post-nadir PSA levels <0.1 ng ml(-1). Radiation administered >1 year post RP and/or after a post-nadir PSA ⩾0.1 ng ml(-1) was defined as SRT. We used claims data to externally validate radiation administration.
RESULTS: Among 2337 patients undergoing RP, 668 (28.6%) were at high risk of recurrence. Of these, 52 (7.8%) received ART and 56 (8.4%) underwent SRT. Patients receiving ART were younger (P=0.027), more likely to have a greater surgical Gleason sum (P=0.009), higher pathologic stage (P<0.001) and received treatment at the smallest and largest size practices (P=0.011). Utilization of both ART and SRT varied widely across MUSIC practices (P<0.001 and P=0.046, respectively), but practice-level rates of ART and SRT administration were positively correlated (P=0.003) with lower ART practices also utilizing SRT less frequently. Of the 88 patients not receiving ART and experiencing a PSA recurrence ⩾0.2 ng ml(-1), 38 (43.2%) progressed to a PSA ⩾0.5 ng ml(-1) and 20 (22.7%) to a PSA ⩾1.0 ng ml(-1) without receiving prior SRT. There was excellent concordance between registry and claims data κ=0.98 (95% CI: 0.94-1.0).
CONCLUSIONS: Utilization of ART and SRT is infrequent and variable across urology practices in Michigan. Although early SRT is an alternative to ART, it is not consistently utilized in the setting of post-RP biochemical recurrence. Quality improvement initiatives focused on current postoperative radiotherapy administration guidelines may yield significant gains for this high-risk population.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26951715     DOI: 10.1038/pcan.2016.9

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  27 in total

1.  Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial.

Authors:  Thomas Wiegel; Detlef Bartkowiak; Dirk Bottke; Claudia Bronner; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Normann Willich; Axel Semjonow; Michael Stöckle; Christian Rübe; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Rainer Hofmann; Rita Engenhart-Cabillic; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller
Journal:  Eur Urol       Date:  2014-03-21       Impact factor: 20.096

Review 2.  Radiotherapy before and after radical prostatectomy for high-risk and locally advanced prostate cancer.

Authors:  Bradford A Perez; Bridget F Koontz
Journal:  Urol Oncol       Date:  2014-10-30       Impact factor: 3.498

3.  Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.

Authors:  Bruce J Trock; Misop Han; Stephen J Freedland; Elizabeth B Humphreys; Theodore L DeWeese; Alan W Partin; Patrick C Walsh
Journal:  JAMA       Date:  2008-06-18       Impact factor: 56.272

4.  Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty.

Authors:  Simon P Kim; Jon C Tilburt; R Jeffrey Karnes; Jeanette Y Ziegenfuss; Leona C Han; Nilay D Shah; Igor Frank; Marc C Smaldone; Cary P Gross; James B Yu; Quoc-Dien Trinh; Maxine Sun; Rebecca L O'Malley; Paul L Nguyen
Journal:  Urology       Date:  2013-08-01       Impact factor: 2.649

5.  Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

Authors:  Thomas Wiegel; Dirk Bottke; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Norman Willich; Axel Semjonow; Rainer Souchon; Michael Stöckle; Christian Rübe; Lothar Weissbach; Peter Althaus; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller
Journal:  J Clin Oncol       Date:  2009-05-11       Impact factor: 44.544

6.  Infection related hospitalizations after prostate biopsy in a statewide quality improvement collaborative.

Authors:  Paul R Womble; Maxwell W Dixon; Susan M Linsell; Zaojun Ye; James E Montie; Brian R Lane; David C Miller; Frank N Burks
Journal:  J Urol       Date:  2013-12-15       Impact factor: 7.450

7.  Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.

Authors:  Andrew J Stephenson; Peter T Scardino; Michael W Kattan; Thomas M Pisansky; Kevin M Slawin; Eric A Klein; Mitchell S Anscher; Jeff M Michalski; Howard M Sandler; Daniel W Lin; Jeffrey D Forman; Michael J Zelefsky; Larry L Kestin; Claus G Roehrborn; Charles N Catton; Theodore L DeWeese; Stanley L Liauw; Richard K Valicenti; Deborah A Kuban; Alan Pollack
Journal:  J Clin Oncol       Date:  2007-05-20       Impact factor: 44.544

8.  The impact of technology diffusion on treatment for prostate cancer.

Authors:  Florian R Schroeck; Samuel R Kaufman; Bruce L Jacobs; Yun Zhang; Alon Z Weizer; Jeffrey S Montgomery; Scott M Gilbert; Seth A Strope; Brent K Hollenbeck
Journal:  Med Care       Date:  2013-12       Impact factor: 2.983

Review 9.  Early salvage radiotherapy following radical prostatectomy.

Authors:  David Pfister; Michel Bolla; Alberto Briganti; Peter Carroll; Cesare Cozzarini; Steven Joniau; Hein van Poppel; Mack Roach; Andrew Stephenson; Thomas Wiegel; Michael J Zelefsky
Journal:  Eur Urol       Date:  2013-08-15       Impact factor: 20.096

10.  Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy.

Authors:  Robert B Den; Felix Y Feng; Timothy N Showalter; Mark V Mishra; Edouard J Trabulsi; Costas D Lallas; Leonard G Gomella; W Kevin Kelly; Ruth C Birbe; Peter A McCue; Mercedeh Ghadessi; Kasra Yousefi; Elai Davicioni; Karen E Knudsen; Adam P Dicker
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-08       Impact factor: 7.038

View more
  6 in total

Review 1.  Improving quality through clinical registries in urology.

Authors:  Mark D Tyson; Daniel A Barocas
Journal:  Curr Opin Urol       Date:  2017-07       Impact factor: 2.309

2.  Prediction of biochemical failure using prostate-specific antigen half-life in patients with adverse pathologic features after radical prostatectomy.

Authors:  Kwang Suk Lee; Kyo Chul Koo; Byung Ha Chung
Journal:  World J Urol       Date:  2018-10-22       Impact factor: 4.226

Review 3.  Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer.

Authors:  Robert T Dess; Todd M Morgan; Paul L Nguyen; Rohit Mehra; Howard M Sandler; Felix Y Feng; Daniel E Spratt
Journal:  Curr Urol Rep       Date:  2017-07       Impact factor: 3.092

4.  Risk Stratification of Prostate Cancer Through Quantitative Assessment of PTEN Loss (qPTEN).

Authors:  Tamara Jamaspishvili; Palak G Patel; Yi Niu; Thiago Vidotto; Isabelle Caven; Rachel Livergant; Winnie Fu; Atsunari Kawashima; Nathan How; John B Okello; Liana B Guedes; Veronique Ouellet; Clarissa Picanço; Madhuri Koti; Rodolfo B Reis; Fred Saad; Anne-Marie Mes-Masson; Tamara L Lotan; Jeremy A Squire; Yingwei P Peng; D Robert Siemens; David M Berman
Journal:  J Natl Cancer Inst       Date:  2020-11-01       Impact factor: 13.506

Review 5.  Salvage therapy for prostate cancer after radical prostatectomy.

Authors:  Nicholas G Zaorsky; Jeremie Calais; Stefano Fanti; Derya Tilki; Tanya Dorff; Daniel E Spratt; Amar U Kishan
Journal:  Nat Rev Urol       Date:  2021-08-06       Impact factor: 14.432

6.  Factors Affecting Robotic Partial Nephrectomy Conversion to Radical Nephrectomy: A Retrospective Multi-Institutional Analysis in the Michigan Urologic Surgery Improvement Collaborative (MUSIC).

Authors:  Benjamin Goldman; Michael Rudoff; Ji Qi; David Wenzler
Journal:  Cureus       Date:  2021-12-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.